Critical review of development, validation, and transfer for high throughput bioanalytical LC-MS/MS methods

被引:66
|
作者
Zhou, Shaolian
Song, Qi
Tang, Yong
Weng, Naidong
机构
[1] Covance Bioanalyt Chem, Madison, WI 53704 USA
[2] Covance Bioanalyt Serv LLC, Indianapolis, IN USA
关键词
LC-MS/MS; bioanalytical; development; validation; transfer;
D O I
10.2174/1573412052953346
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Swift growth in the use of LC-MS/MS for the analysis of drugs in biological matrices has been compelled by the need for timely and high-quality data at many stages in drug discovery and development process: from high throughput screening of drug candidates and rapid data generation for pre-clinical studies to almost 'real-time' analysis of clinical samples. Prompt and rational method development, validation, and transfer play a pivotal role in achieving the goals of "faster, better, and cheaper" for pharmacokinetic studies since this could easily account for more than 50% of the time and labor resources for a moderate-sized project. Strategy for rational method development, validation and transfer has been largely kept as institutional knowledge but rarely appeared in literature. In this review article, strategies for developing and validating robust high throughput LC-MS/MS methods will be critically reviewed and discussed. Automated sample preparation, fast chromatography, minimization of matrix effects, and strategy of narrowing the gap between validation and incurred sample analysis are just a few topics covered in this review. Other interesting approaches for improving method efficiency and ruggedness such as direct injection SPE and liquid/liquid extracts as well as multiplexing of LC columns will also be discussed. Potential pitfalls during method development and validation are pointed out. At the end, the question "how fast is fast enough and how fast is too fast?" will be answered after considering all aspects of the method development and validation.
引用
收藏
页码:3 / 14
页数:12
相关论文
共 50 条
  • [21] Development and validation of bioanalytical methods for LNA-i-miR-221 quantification in human plasma and urine by LC-MS/MS
    Franzoni, Samantha
    Morbioli, Lisa
    Turtoro, Antonio
    Solazzo, Lara
    Greco, Alessandro
    Arbitrio, Mariamena
    Tagliaferri, Pierosandro
    Tassone, Pierfrancesco
    Di Martino, Maria Teresa
    Breda, Massimo
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2020, 188
  • [22] Anidulafungin—challenges in development and validation of an LC-MS/MS bioanalytical method validated for regulated clinical studies
    Tanja Alebic-Kolbah
    Michael S. Modesitt
    Analytical and Bioanalytical Chemistry, 2012, 404 : 2043 - 2055
  • [23] DEVELOPMENT OF HIGH THROUGHPUT LC-MS/MS ASSAYS FOR NUTRITIONAL BIOMARKER QUANTIFICATION
    Mawson, D.
    Marrs, K.
    Teale, P.
    Grace, P.
    ANNALS OF NUTRITION AND METABOLISM, 2013, 63 : 355 - 355
  • [24] Critical topics in ensuring data quality in bioanalytical LC-MS method development
    Mulvana, Daniel E.
    BIOANALYSIS, 2010, 2 (06) : 1051 - 1072
  • [25] Development and Validation of LC-MS/MS and LC-Q-Orbitrap/MS Methods for Determination of Glyphosate in Vaccines
    Lee, Ji Hyun
    Park, Han Na
    Park, Hyoung-Joon
    Heo, Seok
    Park, Seong Soo
    Park, Sung-Kwan
    Baek, Sun Young
    CHROMATOGRAPHIA, 2017, 80 (12) : 1741 - 1747
  • [26] Method development and validation of cabozantinib by LC-MS/MS
    Venkateshwarlu, Punna
    Patel, Mehul M.
    PHARMACIA, 2022, 69 (02) : 407 - 413
  • [27] Matrix effect elimination during LC-MS/MS bioanalytical method development
    Cote, Cynthia
    Bergeron, Annik
    Mess, Jean-Nicholas
    Furtado, Milton
    Garofolo, Fabio
    BIOANALYSIS, 2009, 1 (07) : 1243 - 1257
  • [28] Bioanalytical LC-MS of therapeutic oligonucleotides
    Van Dongen, William D.
    CHIMICA OGGI-CHEMISTRY TODAY, 2012, 30 (01) : 65 - 67
  • [29] Fast LC for high-throughput LC-MS
    Wehr, T
    LC GC NORTH AMERICA, 2003, : 75 - 78
  • [30] Fast LC for high-throughput LC-MS
    Wehr, T
    LC GC NORTH AMERICA, 2002, 20 (01) : 40 - +